Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6(4):372-5. Abstract
Gerds AT. Beyond JAK-STAT: Novel therapeutic targets in Ph-negative MPN. Hematology Am Soc Hematol Educ Program 2019;2019(1):407-14. Abstract
Harrison CN et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial. Lancet Haematol 2018;5(2):e73-e81. Abstract
Hultcrantz M et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study. J Clin Oncol 2012;30(24):2995-3001. Abstract
Mascarenhas J et al. Favorable overall survival with imetelstat treatment correlates with other clinical benefits in intermediate 2 or high risk myelofibrosis relapsed/refractory to Janus kinase inhibitor. ASH 2020;Abstract 53.
Mesa R et al. SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35(34):3844-50. Abstract
Nangalia J, Green AR. Myeloproliferative neoplasms: From origins to outcomes. Hematology Am Soc Hematol Educ Program 2017;2017(1):470-9. Abstract
Pardanni A et al. Long-term safety of fedratinib in patients with intermediate- or high-risk myelofibrosis (MF). ASH 2020;Abstract 3006.
Passamonti F et al. Long-term effect of ruxolitinib (RUX) in inadequately controlled polycythemia vera (PV) without splenomegaly: 5-year results from the phase 3 response-2 study. ASH 2020;Abstract 2987.
Pemmaraju N et al. The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed/refractory myelofibrosis. ASH 2020;Abstract 52.
Price GL et al. Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 2014;9(3):e90299. Abstract
Schieber M et al. Myelofibrosis in 2019: Moving beyond JAK2 inhibition. Blood Cancer J 2019;9(9):74. Abstract
Verstovsek S et al. Real-world survival among patients with intermediate- to high-risk myelofibrosis in the United States: Impact of ruxolitinib approval. ASH 2020;Abstract 3089.
Verstovsek S et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate/high risk myelofibrosis patients. ASH 2020;Abstract 54.
Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10(1):156. Abstract